Table 2.
Toxicity of blinatumomab therapy observed in study patients.
| Toxicity of Blinatumomab | Number of Patients (Total = 13) |
|---|---|
| All adverse events (AEs), any grade | 20 |
| grade 3 CTCAE | 7 |
| grade 4 CTCAE | 3 |
| Severe adverse events (SAEs) | 4 |
| AE leading to treatment interruption | 3 |
| AE leading to treatment cessation | 1 |
| Fatal AE | 0 |
| Cytokine release syndrome grade 3 CTCAE | 1 |
| Anemia | 8 |
| Thrombocytopenia | 4 |
| Neutropenia | 5 |
| Hypotension | 1 |
| Seizures | 2 |
| Tremor | 2 |
| Headache | 4 |
| Fever | 5 |
| Increase of AST/ALT grade 3 CTCAE grade 4 CTCAE |
4 1 |
| Hypertension | 1 |
| Legs pain | 2 |
| Hypokalemia | 3 |
| Hyperferritinemia | 4 |
AST—aspartate transaminases; ALT—alanine transaminase.